The Portuguese Severe Asthma Registry: Development, Features, and Data Sharing Policies by Sá-Sousa, A. et al.
Research Article
The Portuguese Severe Asthma Registry: Development,
Features, and Data Sharing Policies
Ana Sá-Sousa ,1 João Almeida Fonseca ,1,2,3 AnaMargarida Pereira,1,2,3
Ana Ferreira,1 Ana Arrobas ,4 AnaMendes,5 Marta Drummond,6,7,8 Wanda Videira,9
Tiago Costa,10 Pedro Farinha,10 José Soares,10 Pedro Rocha,10 Ana Todo-Bom,11,12
Anna Sokolova,13 António Costa,14 Beatriz Fernandes,15 Carla Chaves Loureiro,16
Cec-lia Longo,17 Cec-lia Pardal,17 Célia Costa,5 C-ntia Cruz,18 Cláudia Chaves Loureiro,19,20
Cristina Lopes,21,22 Duarte Mesquita,23 Em-lia Faria,24 Eunice Magalhães,25
FernandoMenezes,26 Filipa Todo-Bom,27 Francisca Carvalho,5 Frederico S. Regateiro,24
Helena Falcão,28 Ivone Fernandes,29 João Gaspar-Marques,30,31 Jorge Viana,24
José Ferreira,32 José Manuel Silva,33 Laura Simão,34 Leonor Almeida,6 L-gia Fernandes,35
Lurdes Ferreira,15 Mafalda van Zeller,6,8,36 Márcia Quaresma,37 Margarida Castanho,26
Natália André,38 Nuno Cortesão,39 Paula Leiria-Pinto,30,31 Paula Pinto,9,40 Paula Rosa,41
Pedro Carreiro-Martins,30,31 Rita Gerardo,42 Rui Silva,43 Susana Lucas,44
Teresa Almeida,4 and Teresa Calvo45
1 Center for Health Technology and Services Research (CINTESIS), Faculdade de Medicina, Universidade do Porto, Porto, Portugal
2 Department of CommunityMedicine, Information, andHealth Sciences (MEDCIDS), Faculdade deMedicinaUniversidade do Porto,
Porto, Portugal
3 Allergy Unit, Instituto & Hospital CUF Porto, Porto, Portugal
4 Pulmonology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
5 Immunology and Allergy Department, Centro Hospitalar Lisboa Norte, EPE, Lisboa, Portugal
6 Pulmonology Department, Centro Hospitalar de S. João, EPE, Porto, Portugal
7 Pulmonology Department, Faculty of Medicine University of Porto, Porto, Portugal
8 I3S Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
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The Portuguese Severe Asthma Registry (Registo de Asma Grave Portugal, RAG) was developed by an open collaborative network
of asthma specialists. RAG collects data from adults and pediatric severe asthma patients that despite treatment optimization and
adequatemanagement of comorbidities require step 4/5 treatment according toGINA recommendations. In this paper, we describe
the development and implementation of RAG, its features, and data sharing policies. The contents and structure of RAG were
defined in a multistep consensus process. A pilot version was pretested and iteratively improved.The selection of data elements for
RAG considered other severe asthma registries, aiming at characterizing the patient’s clinical status whilst avoiding overloading
the standard workflow of the clinical appointment. Features of RAG include automatic assessment of eligibility, easy data input,
and exportable data in natural language that can be pasted directly in patients’ electronic health record and security features to
enable data sharing (among researchers and with other international databases) without compromising patients’ confidentiality.
RAG is a national web-based disease registry of severe asthma patients, available at asmagrave.pt. It allows prospective clinical data
collection, promotes standardized care and collaborative clinical research, andmay contribute to inform evidence-based healthcare
policies for severe asthma.
1. Introduction
Severe asthma has been defined as asthma which requires
treatment with high dose inhaled corticosteroids plus a sec-
ond controller (and/or systemic corticosteroids), to prevent
it from becoming “uncontrolled” or asthma which remains
“uncontrolled” despite this therapy [1].
To improve care, a better understanding of the etiol-
ogy, burden and management patterns of severe asthma is
needed.Themanagement of severe asthma is challenging and
involves treatment of comorbidities, medication adherence,
allergens exposure avoidance, among others. One of the
greatest difficulties is the choice of the optimal treatment
for each given patient, although algorithms for treatment
decisions have been suggested [2, 3]. Monoclonal antibodies
targeting immunoglobulin-E (IgE) and interleukin-5 are
currently available and new biologics are under development.
However, it is not easy to choose between the biologics to
be the first-choice treatment, and head-to-head comparison
studies between them do not exist [4]. A trial involving the
direct comparison of two or more treatments is a pressing
needed, but it may never be carried out [4]. Hence, clinical
observational studies of real-world large patient populations
should contribute to the knowledge on how to select the best
biologic treatment for an individual patient.
Disease registries are recognized as powerful tools to
improve disease-related knowledge. They consist of orga-
nized systems that use observational studymethods to collect
uniform data aiming at evaluating specific outcomes for a
heterogeneous population defined by a particular disease
[5]. This type of study design enables the assessment of the
effect of different therapies in the context of a single dis-
ease. Severe asthma registries are being created throughout
Europe including in the United Kingdom (UK), Belgium,
Germany, Austria, Netherlands, Italy, and Spain (Table 1).
However, research aiming at reducing the disease-related
burden requires prospective long-lasting studies and the
coordination of a wide range of expertise, often only available
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at an international or even global level [6]. With the goal of
establishing a global collaborative initiative, the International
Severe Asthma Registry was created and the enrollment
of 10 national registries is expected by December 2018[7].
The European Respiratory Society (ERS) Research Agency
promotes collaborative Europe-wide research based on data
collected from disease registries [8]. Its actions include
the development of Standard Operational Procedures and
guidelines, consent forms to collect and handle data in
compliance with the EU legal and regulatory framework, and
establishing a central point to access datasets from multiple
projects. In 2016 the collaboration Severe Heterogeneous
Asthma Research collaboration, Patient-centered (SHARP)
was accepted as an ERS Clinical Research Collaborations
[9]. Taking this into consideration, new registries should be
designed to enable sharing information and coordination
among databases (e.g., federated databases).
Asthma affects 6.8% of the Portuguese population [10].
Using the data from the Portuguese National Asthma Survey
we estimate 7.4% of patients were on step 4 or 5 treatment
as defined by Global Initiative for Asthma (unpublished
data). Even though severe asthma patients represent only a
small proportion of those with asthma, they account for a
large proportion of asthma-related morbidity and health care
expenditures [11].
REAG, Rede de Especialistas em Asma Grave, is an open
collaborative network of asthma specialists (allergists, pedi-
atricians, and pulmonologists) who manage severe asthma
patients in Portuguese hospitals. The foundational principle
of REAG is the informal peer collaboration among col-
leagues with different medical specialties and backgrounds,
maintaining an unhierarchical organization and consensual
decision processes to improve sharing of medical experience,
data, and knowledge. Since 2011, this network of experts
has been working towards a better care of severe asthma
patients by (1) promoting a better coordination between
medical specialties for early diagnosis and referral of severe
asthma patients; (2) describing and implementing harmo-
nized procedures to adopt in severe asthma healthcare; and
(3) improving scientific knowledge on severe asthma in
Portugal. In 2015, REAG published a real-life prospective
study on Portuguese patients with severe persistent allergic
asthma, treated with omalizumab [12]. This was the first-
time specialists from different Portuguese centers who made
an effort to harmonize the registration procedures for severe
asthma. From this initial study, the necessity for a computer-
ized disease registry became even more evident.
The purpose of the Portuguese Severe Asthma Registry
(Registo de Asma Grave Portugal (RAG)) is to gather evidence
on severe asthma in Portugal contributing to eliminate the
information gaps and support the adoption of evidence-based
health care policies. Specifically, the registry aims at
(1) improving the healthcare delivery of severe asthma by
identifying the best diagnosis and treatment practices
and by standardizing disease management processes
and clinical records;
(2) supporting collaborative research projects by promot-
ing the cooperation between centers and assist with
the implementation of research projects.
In this paper, we describe the development and implementa-
tion of RAG, its features, and data sharing policies.
2. Material and Methods
RAG results from the collaboration between different stake-
holders: the medical experts from REAG, the investigators
from CINTESIS (Center for Health Technology and Services
Research), and the software development company Virtual-
Care.
The development and implementation processes of RAG
are summarized in Figure 1.
2.1. Definition of Contents. The criteria for patient inclusion
in RAG, the domains, and data elements to be registered were
defined by a multistep consensus method.
The patients’ inclusion criteria were based on the defini-
tion of Severe Asthma byGINA [1]: (1) patient with treatment
on step 4 or 5 according to GINA recommendations; and (2)
verified optimization of treatment adherence and comorbidi-
ties management. An additional inclusion criterion was (3)
the patient’s signed consent to have his/her data included in
the registry.
During a meeting (April 2016), the domains and data
elements were enumerated, based on the medical expertise
of the network and taking into consideration the variables
existing in three existing European Registries: the Belgian,
the German, and the UK Severe Asthma Registries. Both
data elements to be included in the initial patient registry
and relevant follow-up information were identified. Different
data entry methods were considered to reduce the burden of
response.
An online questionnaire sent to 79 medical specialists
from REAG was used to explore the importance of each
data element and adequacy of data entry method. A total
of 34 participants (43%) completed the questionnaire. For
each domain, data elements and methods for data entry were
chosen when gathering at least 80% of the votes. Comments
and suggestions regarding additional variables or different
data entry methods were also considered. The results of the
questionnaire were presented in a meeting (March 2017) and
disagreements were solved by consensus.
2.2. Features. Database specifications concerning data def-
initions and parameters and data validation rules were
determined. To assist confirmation of the first criterion
and support decision-making, an algorithm to automatically
determine the step of treatment based on currently used
asthma medication was created.
The following additional features were implemented:
(i) Support on data entry by automatic validation of the
inserted data and error messages
(ii) Creation of automatic reports, based on the informa-
tion stored, to be integrated into the institutional elec-
tronic health record (the data recorded are exportable
in natural language by generating a text that mimics
clinical notes)
(iii) Graphic display of aggregated data on patients’ inclu-
sion by healthcare center
BioMed Research International 5
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Figure 1: Development and implementation process of RAG.
(iv) Display for each physician a list of their patients and
date of the last medical appointment
(v) At follow-up visit, automatic display of the informa-
tion inserted in the last appointment for specified
measurements
(vi) Export features for potential data exchange with
international severe asthma databases and the phar-
macovigilance authorities
(vii) Automatic emails with status report of each registra-
tion
2.3. Security and Data Sharing Policies. Security features
compliant with the new European General Data Protection
Regulation (GDPR) [37] and required procedures according
to this legislation are being incorporated into the platform.
The registry was built on a framework residing in a server
hosted by VirtualCare. This server was configured with a
Secure Sockets Layer (SSL) certificate fromComodo Security
Solutions, Inc., ensuring that all data transferred between the
web server and browsers remain private and integral. The
access to the database is restricted, requiring authentication
(using health professional number and password) and all
6 BioMed Research International
accesses to the database are stored and traceable. All changes
to the database are also stored; each change generates a new
document; the old document becomes out of date allowing
the tracking of changes (when, where, and by whom changes
were made to the documents).
RAG does not record any identifiable personal data
from patients (e.g., date of birth is replaced by the year of
birth, no ID numbers are registered, and patients’ names are
pseudoanonymized so replaced with a code number) [38].
The patients’ participation on RAG is free and voluntary,
and patients may, in any moment and without penalty,
withdraw the registry or verify and/or delete their data, by
contacting the technical support. Patients are informed on
the purposes of RAG, the data collected, and the implications
of participating in this registry. The informed consent form
is automatically generated at the time of inclusion. Only
patients that agree, by a clear affirmative consent given by a
written statement, to the storage, processing, and sharing of
data belonging to him/her are included in RAG. The signed
consent forms are upload into the application server file
system, encrypted using phpseclib’s library of PHP, which
allows the usage of one of its encryption algorithms combined
with a private key. When encrypted, the consent file cannot
be read unless the file decryption is activated with the correct
combination of algorithm and private key.The algorithm and
private key are known only to VirtualCare.
An informed consent is also required by physicians who
are registered in RAG since they provide identifiable personal
data for that registration, namely, name, health professional
number, and email address. At the time of registration,
physicians must indicate their acceptance by ticking a box
with a clear statement on the storage and processing of their
personal data. The registration of each physician in RAG
must be validated by at least one of five members of REAG,
designated coordinators of RAG.
Data within RAG belongs primarily to each patient and
then to the physician that inserted patients’ data into the
registry. Each physician is responsible for the management of
the data that he/she inputted, belonging to his/her patients.
Access to patients’ data by their physicians is based on the
Role Based Access Control (RBAC) model that associates
privileges and permissions to the roles (e.g., professional
categories). This model allows easier administration and
independence in relation to the system users and permissions
associated with its resources.
After authentication, each physician can access all the
registrations inserted by himself/herself, both for clinical and
research purposes. One local coordinator will be designated
in each center. Each center coordinator has access, for
pressing clinical purposes only, to all data inserted by the
physicians in that center. If a patient changes the attending
physician, the new physician, if interested in having access
to the previously inserted data, must request authorization
to the former physician, with patient’s consent. Local and
national coordinators and RAG technical support may assist
this contact.
Data inserted by other physicians may be shared within
REAG for research purposes, after authorization. For this,
the physician proposing the data analysis must fill-in a form
containing the aim and a brief description of the research
project and the principal investigator or research group.
When a request for abstracting data is filled, each physician
with data matching the request is notified by email and has a
period of 5 days to refuse the sharing of the data. In the case of
shared information, the privacy of the individual is assured,
as registry data cannot be individually identifiable.
2.4. Pilot-Test. After the implementation of the selected data
elements, the supporting features, and validation rules, a
beta version of RAG was presented during a REAG meeting
(December 2017) and, after adjustments, it was pilot-tested
for a month. The pilot version was tested by 22 REAG
members and 85 specific feedback comments were provided
by 8 testers. The first version of RAG became ready after
improvements being made based on the pilot-test feedback.
3. Results
The Portuguese Severe Asthma Registry is a national web-
based disease registry. The access is made from the website
of REAG, asmagrave.pt, after authentication.
RAG gathers data of adults and children with severe
asthma followed at specialized care centers which, after
treatment optimization and adequate management of comor-
bidities, require step 4 or 5 of treatment according to GINA
recommendations[1]. The implemented automatic algorithm
determines the step of treatment for patients aged under
6, between 6 and 12 and over 12 years, based on asthma
medication prescribed to the patient according to GINA rec-
ommendations (Figure 2.A). In any case, the physician makes
the decision about the inclusion in the registry indicating the
reason for inclusion (Figure 2.B). In fact, even if rarely used,
some therapeutic combinations are not explicitly considered
in any of the GINA 2018 treatment steps and in these cases,
the algorithm cannot present a result. The algorithm will be
updated in the future when these recommendations change.
The final data items of RAG are summarized in Table 2.
RAG allows collecting data on different asthma medication,
including Oral Corticosteroids (OCs), monoclonal antibod-
ies, and even new therapies that may become available
(Figure 3). Data considered as essential are compulsory,
whereas desirable but not essential data may be skipped.
The elements to be collected in the follow-up appointments
were also defined as RAG was designed to collect data
prospectively.
4. Discussion
The Portuguese Severe Asthma Registry is a national web-
based disease registry of adult and pediatric severe asthma
patients. It includes a comprehensive list of data elements
defined by a multistep consensus process, supported by
international definitions of severe asthma. The registry offers
features to facilitate data entry and to support decision-
making. The collected data belongs primarily to each patient
and then to the physician who inserted patients’ data into
the registry and can be shared for research purposes after
authorization. A thorough characterization of severe asthma
BioMed Research International 7
A
B
Figure 2: Screenshot of the implemented automatic algorithm to determine the step of treatment, based on asthma medication according to
GINA recommendations. A: treatment step calculated by the algorithm; B: the 3 criteria for patients’ inclusion.
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Figure 3: Screenshot of RAG, picturing asthma medication being collected by RAG.
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Table 3: RAG features useful to support severe asthma management.
Elements of chronic care management [36] RAG features
Current Future
Ensure regular follow-up
Displays for each physician
a list of their patients and
date of the last medical
appointment
Display a simple message with
the counting the months since
the last appointment and flag
patients without medical review
in more than 6 months
Facilitate individual patient care planning
For specified
measurements, displays the
information inserted in the
last appointment and its
progress over time
At the beginning of each
follow-up appointments, a brief
report of the previous
appointment will be displayed
Embed evidence-based guidelines into clinical practice
has a decision support tool
to identify patients treated
in step 4 or 5 according to
GINA recommendations
Monitor the performance of practice team
Displays aggregated data on
the number of patients
included by each center
Aggregated real-time data with
different graphic displays of
trends on specified management
and clinical outcomes will be
produced, to give a feedback to
physicians about the status of the
care of their patients and/or
healthcare center, towards
delivering the recommended
care for severe asthma.
patients, using a tool consensually defined to be applied
prospectively by specialists from Portuguese hospitals, is
ambitious but can improve the information on the disease
and contribute to the adoption of evidence-based policies for
severe asthma care. This harmonized approach is essential
to improve the management of the different phenotypes
this pathology. The Portuguese registry was designed to
enable future linkage with other databases, as registries from
other countries, as well as the Portuguese Pharmacovigilance
Authority.
The data elements included in RAG were selected to
reflect the current clinical status of the patient avoiding
unnecessary burden within the clinical workflow. Through a
multistep consensusmethod, a balancewas achieved between
the data commonly used by clinicians, the data included in
other severe asthma registries, the data needed for the RAG’s
reliability, and the expected overall burden for respondents.
Therefore, there was an effort to data collected by RAG
which can be compared to data collected by other registries
enabling comparisons across populations and settings. A
consensus method was used to summarize information from
different sources, to gather insights from experts and to
enable decision-making [39]. After the selection and imple-
mentation of the data elements and validation rules, RAGwas
pilot-tested and iteratively improved before release.
The patients’ inclusion criteria were also defined by
consensus and an automatic algorithm was implemented
to assist patients’ eligibility assessment, based on GINA
recommendations. Clinical guidelines provide a link between
the best available evidence and the clinical practice, having
the potential to improve enormously patient care [40]. How-
ever, these may have limitations especially for a particular
disease where evidence is still insufficient as in severe asthma
and cannot be used as a strict formula. During algorithm
development became clear that GINA 2018 treatment steps
do not account for all possible therapeutic combinations.
In the future, it would be important to assess if clinically
relevant combinations are not included in the GINA rec-
ommendations, to contribute to the improvement of the
recommendations concerning severe asthma.
Disease registries are used to support healthcare
providers on disease care and to gather evidence for scientific
and policy purposes. Therefore, a disease registry should
(1) facilitate the access to patient-specific information at
the point of care for healthcare delivery and provide status
reports of aggregated information to give feedback to
physicians or to medical groups about the patient population
[36] and (2) provide real-world data on clinical practice,
patient outcomes, safety, and/or comparative effectiveness for
research purposes[5]. RAG has several features to support
healthcare providers on severe asthma care (Table 3).
Additionally, as suggested by the members of REAG, RAG
includes the automatic generation of clinical notes based on
the inputted data that can be pasted into the institutional
electronic clinical record of the patient, avoiding duplication
of effort.
Real-world prospective observational research, including
long-term follow-up data provided by registries, is increas-
ingly considered important to generate evidence regarding
effectiveness, safety, and quality of care [41]. The utility of a
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registry relies on the quality of data collection and storage
[5]. RAG’s data are collected at the time of routine medical
appointments, in the same manner for every patient, with
specific and consistent data definitions. To minimize errors
related to data completeness and consistency, several logical
and validation rules have been implemented and periodic
data audits are being planned. An additional challenge is the
recruitment and retention of participants that is critical to the
generalizability of a registry [5]. Potential RAG users were
involved from the beginning in the development and imple-
mentation process and stated their motivation to include
patients. Nevertheless, to retain users’ interest, the burden of
participation was kept as low as possible and features wanted
by the physicians were implemented.
RAG was designed to comply with security and data
protection standards, including key challenges of the new
European GDPR. No individually identifiable information
of the patient is recorded in the database. Only the his/her
physician can link the recorded data to the patient that
remains the owner of the data. RAG’s data sharing policies
allow the use of data for research, requiring the consent of
the physician that recorded the data and a simple process to
gather this consent was implemented.
5. Conclusions
The Portuguese Severe Asthma Registry is a national web-
based disease registry of adult and pediatric severe asthma
patients. The development and implementation of the RAG
was a multistep consensus process. RAG includes automatic
assessment of eligibility, easy data input, and features for
exporting and sharing data. It allows prospective clinical data
collection, promotes standardized clinical records, and cre-
ates a secure virtual setting for collaborative clinical research.
RAG database is prepared for future data exchange with
international databases. In the future, the analysis of RAG
data may contribute to inform evidence-based healthcare
policies for severe asthma.
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